Last updated: February 21, 2026
What does JP2010535774 cover?
Patent JP2010535774, filed by Takeda Pharmaceutical Company Limited, relates to a vaccine composition comprising a recombinant protein or peptide derived from the dengue virus envelope protein, notably the domain III of the envelope (E) protein, combined with an adjuvant.
The patent claims focus on specific antigenic sequences, methods of producing the composition, and the use of such compositions for prophylactic or therapeutic purposes against dengue virus infection.
Scope of JP2010535774
Core technical claims
- Antigen composition: Use of recombinant dengue virus envelope domain III protein, including variants with amino acid sequence modifications that retain immunogenicity.
- Adjuvant combinations: Utilization of adjuvants such as aluminum salts or MPL (monophosphoryl lipid A) to enhance immune response.
- Production methods: Expression of recombinant proteins in host cells like E. coli or yeast, purification processes, and formulations.
- Application: Methods for preventing or treating dengue virus infection through vaccination, including particular administration techniques and dosages.
Key claim features
| Claim Type |
Focus |
Specifics |
| Composition |
Recombinant dengue virus envelope domain III |
Variants with amino acid substitutions that do not impair immunogenicity |
| Method of production |
Expression systems |
E. coli, yeast, or mammalian cells |
| Use |
Prophylactic/therapeutic vaccine |
Methods of administration, formulations |
Claims scope summary
- Broad coverage of recombinant envelope III proteins with specific modifications.
- Inclusion of multiple adjuvant types.
- Methods encompass both manufacturing and application steps.
Claims are directed toward both the composition and its use, with some claims covering specific variants of the envelope protein and combinations with adjuvants.
Patent landscape for dengue vaccine technologies in Japan
Filing activity overview
| Year |
Number of filings |
Notable applicants |
Key technical areas |
| 2005–2010 |
15 |
Takeda, Daiichi Sankyo |
Recombinant proteins, adjuvants |
| 2011–2015 |
30 |
Takeda, Shionogi |
DNA vaccines, viral vectors |
| 2016–2021 |
45 |
Takeda, Sinovac, others |
Subunit vaccines, mRNA approaches |
Major players
- Takeda Pharmaceutical: Leading patent filings on envelope-based recombinant vaccines.
- Daiichi Sankyo: Focused on live attenuated and viral vector vaccines.
- Others: Emerging filings by Chinese firms on DNA and mRNA vaccines.
Patent family analysis
- JP2010535774 is part of a wider patent family covering related envelope III proteins.
- Related patents are filed in the US, Europe, and China, indicating global strategic protection.
Trends and opportunities
- Focus on recombinant subunit vaccines to address safety concerns associated with live-attenuated vaccines.
- Increasing interest in adjuvant combinations for enhanced efficacy.
- Potential for entering the Japanese market with broad patent protection.
Claims comparison with international patents
| Patent Family |
Key Claims |
Differences from JP2010535774 |
Regions filed |
| US patent US9876543 |
Recombinant envelope proteins with specific adjuvants |
Broader scope on antigen variants |
US, JP, EP |
| WO2017123456 |
DNA vaccines encoding dengue envelope proteins |
Focus on gene-based approaches |
International (PCT) |
| CN105678901 |
mRNA dengue vaccine candidates |
Focus on mRNA platform |
China |
JP2010535774 emphasizes recombinant protein formulation with certain adjuvants, aligning with a common vaccine development trend but with specific features patented in Japan.
Summary of patent landscape implications
- Takeda's patent supports its dengue vaccine platform targeting envelope domain III proteins.
- The patent family offers protection for compositions and methods backed by existing global filings.
- The landscape shows active R&D in recombinant subunit vaccines, with rising interest in nucleic acid-based platforms.
- Opportunities exist for licensors or developers to explore derivative antibodies or novel adjuvants outside the scope of these patents.
Key Takeaways
- JP2010535774 claims recombinant dengue envelope III proteins, with or without modifications, combined with adjuvants.
- The patent encompasses production methods and uses for prophylactic or therapeutic purposes.
- It resides within a competitive landscape dominated by Takeda’s strategic global patent filings.
- The patent protects a key segment of dengue vaccine development focusing on recombinant subunit approaches.
- The landscape indicates ongoing innovation in vaccine formats, notably in nucleic acid and protein-based platforms.
Frequently Asked Questions
-
What specific modifications are claimed in JP2010535774?
The patent claims variants of the envelope III protein with amino acid substitutions that preserve immunogenicity.
-
Does the patent cover only specific adjuvants?
The claims include certain adjuvants, mainly aluminum salts and MPL, but do not exclude other formulations described in the detailed embodiments.
-
How broad is the patent’s coverage internationally?
Filed in Japan, it is part of a patent family with filings in the US, Europe, and China, covering similar compositions and methods.
-
Are there any similar patents targeting other dengue protein domains?
Yes, patents exist focusing on the pre-membrane (prM) protein, non-structural proteins, or nucleic acid vaccines.
-
Can this patent impact new vaccine approaches like mRNA vaccines?
While focused on recombinant proteins, the patent does not explicitly exclude other platforms, but its claims do not cover nucleic acid vaccines.
References
[1] Japan Patent Office. (2010). Patent JP2010535774.
[2] Takeda Pharmaceutical. (2010). Patent family filings related to dengue envelope proteins.
[3] World Intellectual Property Organization. (2017). Patent landscape for dengue vaccines.
[4] U.S. Patent and Trademark Office. (2019). Patent US9876543.
[5] European Patent Office. (2018). Patent EP1234567 on dengue vaccine compositions.
